Drugs / CD19CD20-CAR.p40-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07097207 | Oct 2023 → Sep 2026 overdue | B-cell non-Hodgkin lymphoma | Shenzhen University General Hospital | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19CD20-CAR.p40-T | “Autocrine p40 Chimeric Antigen Receptor T Cells Targeting CD19 and CD20 (CD19CD20-CAR.p40-T)” NCT07097207 ↗ |
| Modality | Cell therapy | “CD19/CD20 dual-targeting CAR.p40-T cell therapy” NCT07097207 ↗ |
| Target | CD19 | “autocrine p40 CAR-T cells targeting dual CD19/CD20” NCT07097207 ↗ |
| Target | CD20 | “autocrine p40 CAR-T cells targeting dual CD19/CD20” NCT07097207 ↗ |